论文部分内容阅读
目的观察喜炎平联合雾化吸入治疗呼吸道合胞病毒毛细支气管炎的临床疗效。方法 60例临床诊断为呼吸道合胞病毒毛细支气管炎患儿,随机分为实验组和对照组,各30例。对照组给予利巴韦林加布地奈德雾化吸入,实验组给予喜炎平加布地奈德雾化吸入,观察两组临床疗效。结果实验组症状和体征消失时间、住院天数、再喘息发生率均优于对照组,差异有统计学意义(P<0.05);实验组治疗总有效率为93.3%,明显高于对照组的80.0%,差异有统计学意义(P<0.05)。结论在治疗呼吸道合胞病毒毛细支气管炎时,运用喜炎平联合雾化吸入的疗法,疗效显著,并能缩短住院时间,安全性高,可操作性强,有助于提高临床的治疗效果,值得推广。
Objective To observe the clinical efficacy of Xiyanping combined with inhalation in the treatment of respiratory syncytial virus bronchiolitis. Methods Sixty children with respiratory syncytial virus bronchiolitis were randomly divided into experimental group and control group, with 30 cases in each group. The control group was given ribavirin and budesonide atomized inhalation, and the experimental group was given Xiyanping and budesonide inhalation to observe the clinical curative effect of the two groups. Results The disappearance time of symptoms and signs, length of hospital stay and respite of wheezing in experimental group were significantly higher than those in control group (P <0.05). The total effective rate in experimental group was 93.3%, which was significantly higher than that in control group %, The difference was statistically significant (P <0.05). Conclusion In the treatment of respiratory syncytial virus bronchiolitis, the combination of Xiyanping inhalation therapy, the effect is significant, and can shorten the hospital stay, high safety, maneuverability, and help to improve the clinical treatment effect, Worth promoting.